Galenica AB Company Profile
Galenica´s strategy is to enter as a highly qualified partner in all aspects of the development of new drugs. Galenica offers full coverage from traditional pharmaceutical formulation, formulation development, biopharmaceutical evaluation, GMP-manufacturing, quality control to regulatory elements of drug development.
Location
Medeon Sciense Park P.A. Hanssonsväg 41
Malmo
S-205 12
Sweden
Contact
Phone: +46 4032 1095
Fax: +46 4032 1096
Email: ronnie.wallin@galenica.se
News Articles
Galenica's kidney drug meets endpoint in trial
ZURICH (Reuters) - Swiss healthcare company Galenica said on Monday that its kidney drug PA21 successfully met primary and secondary endpoints in a late-stage trial, paving the way for regulatory fili...
Galenica submits US NDA for chewable, iron-based phosphate binder
Swiss drug maker Galenica submitted a new drug application (NDA) to the US FDA for PA21, a chewable, iron-based phosphate binder, as a treatment to control of hyperphosphatemia in patients with chro...
Galenica submits European application for PA21
Galenica Ltd. (SIX:GALN) submitted a regulatory application to EMA for PA21 to treat hyperphosphatemia in patients with chronic kidney disease (CKD). The oral iron-based phosphate binder is being deve...
Vifor good for Q4 filing, but can it vie for market?
Vifor Pharma and Fresenius Medical Care Renal Pharma (a Galenica/Fresenius joint Venture) are planning regulatory filings for their hyperphosphataemia drug PA21 in the US, EU and Switzerland, startin...
Regulatory filing preparations underway for Vifor's PA21 on good Ph III results
The pivotal Phase III clinical study shows that the new phosphate binder PA21 successfully controls hyperphosphatemia in patients with chronic kidney disease on dialysis, reports Switzerland-based Vif...
FDA to review Galenica's PA21 for CKD
Galenica Ltd. (SIX:GALN) and its specialty pharma business Vifor Pharma Ltd. said FDA accepted for review an NDA for PA21 to treat hyperphosphatemia in patients with chronic kidney disease (CKD). The...
Vifor gets certain rights to Helsinn's netupitant-palonosetron
Privately-held Helsinn Healthcare and fellow Switzerland-based Vifor Pharma, part of the Galenica group (SIX: GALN), have entered into an exclusive license and distribution agreement for netupitant-pa...
Drugs and Medications
None
PubMed Articles
None
Clinical Trials
None
Companies
Galenica´s strategy is to enter as a highly qualified partner in all aspects of the development of new drugs. Galenica offers full coverage from traditional pharmaceutical formulation, formulation de...
Galenica is a diversified group active throughout the healthcare market which, amont other things, develops, manufactures and markets pharmaceutical products, runs pharmacies, provides logistical serv...
Vifor AG gehört zum Geschäftsbereich Pharma der Galenica Gruppe.Sie ist auf den Gebieten der galenischen Entwicklung, Produktion und Kommerzialisierung von pharmazeutischen Beratungsprodukten sowie...
More Information about "Galenica AB" on BioPortfolio
We have published hundreds of Galenica AB news stories on BioPortfolio along with dozens of Galenica AB Clinical Trials and PubMed Articles about Galenica AB for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Galenica AB Companies in our database. You can also find out about relevant Galenica AB Drugs and Medications on this site too.
